Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy
Drug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2019
|
| _version_ | 1826282119118192640 |
|---|---|
| author | Conrado, DJ Larkindale, J Berg, A Hill, M Burton, J Abrams, KR Abresch, RT Bronson, A Chapman, D Crowther, M Duong, T Gordish-Dressman, H Harnisch, L Henricson, E Kim, S McDonald, CM Schmidt, S Vong, C Wang, X Wong, BL Yong, F Romero, K Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC) |
| author2 | Servais, LJP |
| author_facet | Servais, LJP Conrado, DJ Larkindale, J Berg, A Hill, M Burton, J Abrams, KR Abresch, RT Bronson, A Chapman, D Crowther, M Duong, T Gordish-Dressman, H Harnisch, L Henricson, E Kim, S McDonald, CM Schmidt, S Vong, C Wang, X Wong, BL Yong, F Romero, K Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC) |
| author_sort | Conrado, DJ |
| collection | OXFORD |
| description | Drug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple sources, and the use of such integrated databases to develop statistical models can inform protocol development and reduce the risks in developing new therapies. Achieving regulatory endorsement of such models through defined pathways at the US Food and Drug Administration and European Medicines Authority allows such tools to be used by the drug development community for defined contexts of use without further need for discussion of the underlying model(s). The Duchenne Regulatory Science Consortium (D-RSC) has brought together multiple stakeholders to develop a clinical trial simulation tool for Duchenne muscular dystrophy using such an approach. Here we describe the work of D-RSC as an example of how such an approach may be effective at reducing uncertainty in drug development for rare diseases, and thus bringing effective therapies to patients faster.
|
| first_indexed | 2024-03-07T00:39:02Z |
| format | Journal article |
| id | oxford-uuid:826887a5-8caa-46e8-b6ad-1b5c1ed36fda |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:39:02Z |
| publishDate | 2019 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:826887a5-8caa-46e8-b6ad-1b5c1ed36fda2022-03-26T21:37:17ZTowards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:826887a5-8caa-46e8-b6ad-1b5c1ed36fdaEnglishSymplectic ElementsSpringer2019Conrado, DJLarkindale, JBerg, AHill, MBurton, JAbrams, KRAbresch, RTBronson, AChapman, DCrowther, MDuong, TGordish-Dressman, HHarnisch, LHenricson, EKim, SMcDonald, CMSchmidt, SVong, CWang, XWong, BLYong, FRomero, KDuchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC)Servais, LJPDrug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple sources, and the use of such integrated databases to develop statistical models can inform protocol development and reduce the risks in developing new therapies. Achieving regulatory endorsement of such models through defined pathways at the US Food and Drug Administration and European Medicines Authority allows such tools to be used by the drug development community for defined contexts of use without further need for discussion of the underlying model(s). The Duchenne Regulatory Science Consortium (D-RSC) has brought together multiple stakeholders to develop a clinical trial simulation tool for Duchenne muscular dystrophy using such an approach. Here we describe the work of D-RSC as an example of how such an approach may be effective at reducing uncertainty in drug development for rare diseases, and thus bringing effective therapies to patients faster. |
| spellingShingle | Conrado, DJ Larkindale, J Berg, A Hill, M Burton, J Abrams, KR Abresch, RT Bronson, A Chapman, D Crowther, M Duong, T Gordish-Dressman, H Harnisch, L Henricson, E Kim, S McDonald, CM Schmidt, S Vong, C Wang, X Wong, BL Yong, F Romero, K Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC) Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title | Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title_full | Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title_fullStr | Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title_full_unstemmed | Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title_short | Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
| title_sort | towards regulatory endorsement of drug development tools to promote the application of model informed drug development in duchenne muscular dystrophy |
| work_keys_str_mv | AT conradodj towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT larkindalej towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT berga towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT hillm towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT burtonj towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT abramskr towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT abreschrt towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT bronsona towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT chapmand towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT crowtherm towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT duongt towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT gordishdressmanh towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT harnischl towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT henricsone towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT kims towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT mcdonaldcm towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT schmidts towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT vongc towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT wangx towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT wongbl towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT yongf towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT romerok towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy AT duchennemusculardystrophyregulatoryscienceconsortiumdrsc towardsregulatoryendorsementofdrugdevelopmenttoolstopromotetheapplicationofmodelinformeddrugdevelopmentinduchennemusculardystrophy |